Cargando…

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag

PURPOSE: Targeting the prostacyclin pathway is an effective treatment option for pulmonary arterial hypertension (PAH). Patients with PAH have a deficiency of prostacyclin and prostacyclin synthase. Selexipag is an orally available and selective prostacyclin receptor (IP receptor) agonist. Selexipag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufmann, Priska, Okubo, Kaori, Bruderer, Shirin, Mant, Tim, Yamada, Tetsuhiro, Dingemanse, Jasper, Mukai, Hideya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452035/ https://www.ncbi.nlm.nih.gov/pubmed/25850750 http://dx.doi.org/10.1007/s40256-015-0117-4

Ejemplares similares

A thorough QT study in the context of an uptitration regimen with selexipag, a selective oral prostacyclin receptor agonist
por: Hoch, Matthias, et al.
Publicado: (2014)

First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension
por: Geerdink, Lianne M., et al.
Publicado: (2017)

Population Modeling of Selexipag Pharmacokinetics and Clinical Response Parameters in Patients With Pulmonary Arterial Hypertension
por: Krause, A, et al.
Publicado: (2017)

Transition from parenteral prostacyclins to selexipag: safety and feasibility in selected patients
por: Aldweib, Nael, et al.
Publicado: (2021)

Impact of additional selexipag on prostacyclin infusion analogs in patients with pulmonary arterial hypertension
por: Momoi, Mizuki, et al.
Publicado: (2022)

Hemodynamic assessment of transitioning from parenteral prostacyclin to selexipag in pediatric pulmonary hypertension
por: Colglazier, Elizabeth, et al.
Publicado: (2022)

Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients
por: Holthaus, Nathan, et al.
Publicado: (2019)

Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
por: Koestenberger, Martin, et al.
Publicado: (2018)

The use of selexipag, a prostacyclin receptor analog, for treatment of severe pulmonary artery hypertension during pregnancy, a case report
por: Khan, Akram, et al.
Publicado: (2023)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles
por: Luo, Shun-bin, et al.
Publicado: (2021)

Clopidogrel, a CYP2C8 inhibitor, causes a clinically relevant increase in the systemic exposure to the active metabolite of selexipag in healthy subjects
por: Axelsen, Lene Nygaard, et al.
Publicado: (2020)

Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study
por: Coghlan, J. Gerry, et al.
Publicado: (2018)

Safety, tolerability, and pharmacokinetics of the selective prostacyclin receptor agonist ralinepag in single and multiple dosing studies of an immediate-release oral formulation in healthy volunteers
por: Grundy, John S., et al.
Publicado: (2020)

IP receptor-dependent activation of PPARγ by stable prostacyclin analogues
por: Falcetti, Emilia, et al.
Publicado: (2007)

Treatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway
por: Anliker-Ort, Marion, et al.
Publicado: (2020)

Selexipag for pulmonary arterial hypertension
Publicado: (2021)

Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects
por: Berger, Benjamin, et al.
Publicado: (2023)

Genetic Deletion of Prostacyclin IP Receptor Exacerbates Transient Global Cerebral Ischemia in Aging Mice
por: Shakil, Hania, et al.
Publicado: (2013)

Selexipag in the management of pulmonary arterial hypertension: an update
por: Coghlan, J Gerry, et al.
Publicado: (2019)

Selexipag for the treatment of chronic thromboembolic pulmonary hypertension
por: Ogo, Takeshi, et al.
Publicado: (2022)

Synthetic Prostacyclin Agonist Attenuates Pressure-Overloaded Cardiac Fibrosis by Inhibiting FMT
por: Masada, Kenta, et al.
Publicado: (2020)

Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study
por: Klose, Hans, et al.
Publicado: (2021)

High Throughput Mutagenesis for Identification of Residues Regulating Human Prostacyclin (hIP) Receptor Expression and Function
por: Bill, Anke, et al.
Publicado: (2014)

Arachidonic Acid Metabolite 19(S)-HETE Induces Vasorelaxation and Platelet Inhibition by Activating Prostacyclin (IP) Receptor
por: Tunaru, Sorin, et al.
Publicado: (2016)

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

The selective PGI(2) receptor agonist selexipag ameliorates Sugen 5416/hypoxia-induced pulmonary arterial hypertension in rats
por: Honda, Yohei, et al.
Publicado: (2020)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Evaluation of the cytochrome P450 2C19 and 3A4 inhibition potential of the complement factor 5a receptor 1 antagonist ACT‐1014‐6470 in vitro and in vivo
por: Anliker‐Ort, Marion, et al.
Publicado: (2023)

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment
por: Fontes, Magda S. C., et al.
Publicado: (2022)

Hemodynamic and clinical effects of selexipag in children with pulmonary hypertension
por: Rothman, Abraham, et al.
Publicado: (2020)

Pharmacokinetics and tolerability of intranasal or intravenous administration of nalbuphine in infants
por: Pfiffner, Miriam, et al.
Publicado: (2023)

PROSTACYCLIN IN HEALTH AND DISEASE
Publicado: (1983)

Prostacyclin: An Inflammatory Paradox
por: Stitham, Jeremiah, et al.
Publicado: (2011)

Modeling time‐delayed concentration‐QT effects with ACT‐1014‐6470, a novel oral complement factor 5a receptor 1 (C5a(1) receptor) antagonist
por: Anliker‐Ort, Marion, et al.
Publicado: (2023)

Prostacyclin Synthesis and Prostacyclin Receptor Expression in the Porcine Myometrium: Prostacyclin Potential to Regulate Fatty Acid Transporters, Cytokines and Contractility-Related Factors
por: Blitek, Agnieszka, et al.
Publicado: (2022)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
por: Hardin, Elizabeth Ashley, et al.
Publicado: (2016)

Baseline history of patients using selexipag for pulmonary arterial hypertension
por: Highland, Kristin B., et al.
Publicado: (2019)

Use of selexipag in a teenage patient with pulmonary arterial hypertension
por: Bravo-Valenzuela, Nathalie Jeanne Magioli, et al.
Publicado: (2021)

Transitioning selexipag to oral treprostinil in patients with pulmonary artery hypertension
por: Arevalo, Carlo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0bp9ds5k150ecvbd2l10jn6obs